Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

$24.99

Income Statement
Quarterly Data

Pfizer Inc., consolidated income statement (quarterly data)

US$ in millions

Microsoft Excel
3 months ended: Jun 29, 2025 Mar 30, 2025 Dec 31, 2024 Sep 29, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Oct 1, 2023 Jul 2, 2023 Apr 2, 2023 Dec 31, 2022 Oct 2, 2022 Jul 3, 2022 Apr 3, 2022 Dec 31, 2021 Oct 3, 2021 Jul 4, 2021 Apr 4, 2021 Dec 31, 2020 Sep 27, 2020 Jun 28, 2020 Mar 29, 2020
Product revenues
Alliance revenues
Royalty revenues
Revenues (legacy)
Revenues
Cost of sales
Gross profit
Selling, informational and administrative expenses
Research and development expenses
Acquired in-process research and development expenses
Amortization of intangible assets
Restructuring charges and certain acquisition-related costs
Operating income (loss)
Gain on completion of Consumer Healthcare JV transaction
Other income (deductions), net
Income (loss) from continuing operations before (provision) benefit for taxes on income (loss)
(Provision) benefit for taxes on income (loss)
Income (loss) from continuing operations
Discontinued operations, net of tax
Net income (loss) before allocation to noncontrolling interests
Net income attributable to noncontrolling interests
Net income (loss) attributable to Pfizer Inc. common shareholders

Based on: 10-Q (reporting date: 2025-06-29), 10-Q (reporting date: 2025-03-30), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-29), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-10-01), 10-Q (reporting date: 2023-07-02), 10-Q (reporting date: 2023-04-02), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-10-02), 10-Q (reporting date: 2022-07-03), 10-Q (reporting date: 2022-04-03), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29).


Revenue Trends
Overall revenues demonstrate significant volatility with a peak observed in the period ending July 2021, reaching near 28 billion USD, followed by a sharp decline in subsequent quarters. Product revenues notably surged beginning from the period ending April 2023, exhibiting variability including a low around July 2023 and a recovery by year-end 2024. Alliance and royalty revenues generally show a gradual increase over recent quarters, indicating diversification and growth in non-product revenue streams.
Cost of Sales and Gross Profit
Cost of sales follows a fluctuating downward trend in absolute terms after mid-2022, with a pronounced decrease beginning April 2023, leading to a contraction in gross profit in the same timeframe. Gross profit, while peaking around mid-2022, experiences a marked decline in early 2023 but partially recovers towards the end of 2024. This pattern suggests cost management challenges or alterations in sales mix impacting profitability.
Operating Expenses
Selling, informational, and administrative expenses exhibit cyclical increases and decreases but generally trend downward from late 2021 through 2024, which could reflect cost-containment efforts. Research and development expenses also decline moderately over the later periods, albeit with irregular fluctuations, possibly reflecting shifting investment priorities. Acquired in-process R&D expenses are sporadic but include notably high charges during certain quarters, impacting total R&D spend.
Amortization and Restructuring Costs
Amortization of intangible assets remains relatively stable over the periods with slight increases towards 2024, indicating ongoing capitalized asset amortization. Restructuring charges and acquisition-related costs are variable, with some large spikes in certain quarters that distort operating expense totals and imply periodic restructuring activities or integration costs.
Profitability and Income Measures
Operating income shows substantial volatility with strong peaks through 2021 and 2022, followed by periods of loss notably in late 2023 and early 2024, before recovering again into positive territory by late 2024. Income from continuing operations follows a similar pattern, with net income before allocation showing analogous fluctuations. The tax provision exhibits variability consistent with pretax income swings, sometimes contributing positively or negatively to net income.
Net Income Attribution
Net income attributable to the company’s common shareholders mirrors overall net income trends, highlighting significant earnings variability including loss periods around late 2023. The presence of noncontrolling interests is minor and has minimal impact on consolidated net income figures.
Summary
The data reflect a period of substantial operational and financial variability, characterized by rapid revenue growth to mid-2021 followed by a sharp contraction, particularly in product revenues. Expense management shows some improvement post-2021, but earnings remain highly variable with significant losses in part of 2023. The resurgence of revenues and profit in late 2024 signals potential recovery. The company’s financial performance may be influenced by external market factors, portfolio adjustments, or strategic initiatives affecting revenue streams, costs, and investment expenses.